NCT02110004已完成1 期
Picasso NAV High-Density Mapping Catheter for Signal Analysis of Complex Arrhythmias - First-In-Man
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 主要终点
- Intra-procedural investigational device success
研究概览
简要总结
The primary purpose of the First-In-Man clinical investigation is to assess the Picasso NAV Catheter's ability to collect intracardiac signals within the desired chambers (atrial and/or ventricle) in the heart for the analysis of complex arrhythmias.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible for participation in this clinical investigation.
- •Age > 18 years or older.
- •Patients who have signed the Patient Informed Consent Form (ICF)
- •Patients who are scheduled to undergo a clinically-indicated catheter ablation procedure for the management of a complex arrhythmia. (Patients having undergone a previous ablation procedure may be included.)
- •Subjects who have failed at least one antiarrhythmic drug (AAD) (including AV nodal blocking agents such as beta blockers and calcium channel blockers) as evidenced by recurrent symptomatic complex arrhythmia, or intolerable to the AAD
- •Complex arrhythmias (including atrial fibrillation, atypical flutter, ventricular tachycardia) defined as patients who have been diagnosed with a complex arrhythmia anytime within the last 5 years prior to enrolment. Symptoms may include, but are not restricted to, palpitations, shortness of breath, chest pain, fatigue, left ventricular dysfunction, or other symptoms, or any combination of the above.
- •At least one episode of the complex arrhythmia must have been documented by ECG, Holter, loop recorder, telemetry, implanted device, or transtelephonic monitoring within 12 months of enrollment.
- •Able and willing to comply with all pre-, post-, and follow-up testing and requirements.
排除标准
- •Subjects who meet any of the following exclusion criteria are not eligible for enrollment.
- •A complex arrhythmia secondary to a reversible cause.
- •Atrial arrhythmias: patients with a left atrial size >55 mm (echocardiography, parasternal long axis view).
- •Left Ventricular Ejection Fraction < 25%
- •NYHA Class III or IV
- •Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.
- •Atrial arrhythmias: patients with structural atrial disease such as a prior history of atriotomy from prior atrial surgery, presence of an atrial septal defect, and/or presence of an atrial septal closure patch.
- •History of or current blood clotting or bleeding abnormalities, contraindication to systemic anticoagulation (i.e., heparin, warfarin, dabigatran, or a direct thrombin inhibitor)
- •Subjects that have ever undergone valvular cardiac surgical procedure (ie, ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve)
- •Any cardiac surgery within the past 60 days (2 months) (includes PCI)
- •Concurrent enrollment in a study evaluating another device or drug.
- •A complex arrhythmia secondary to electrolyte imbalance, thyroid disease, or non-cardiac cause.
- •Presence of intra-cardiac thrombus or myxoma, interatrial baffle or patch, tumor or other abnormality that precludes catheter introduction or manipulation.
- •Presence of a condition that precludes vascular access.
- •Women of child bearing potential whom are pregnant, lactating, or planning to become pregnant during the course of the clinical investigation
- •Active illness or active systemic infection or sepsis.
结局指标
主要结局
Intra-procedural investigational device success
时间窗: Intra-procedure
Intra-procedural investigational device success * Ability to deploy the Picasso NAV Catheter within the atria and/or ventricles * The collection of intra-cardiac signals in the atria and/or ventricles Measured by number and percentage of physicians able to deploy and collect intra-cardiac signals as outlined in the protocol
次要结局
- Characterize the ideal workflow(Intra-procedure)
- Visualize the device(Up to 3 months)
- Overall safety(Up to 7 days)
研究者
相似试验
已完成
不适用
Central Venous Access Catheter Placement Using the Sonic FlashlightCatheterization, Central VenousNCT00330590University of Pittsburgh150
已完成
不适用
Validation of the Advisor HD Grid Mapping Catheter in Atrial Fibrillation AblationAtrial FibrillationNCT04850508University of Calgary20
已完成
不适用
EnSite™ HD Grid Catheter AF/AT Mapping StudyNon-paroxysmal Atrial FibrillationLeft Atrial TachycardiaNCT02656537Abbott Medical Devices82
已完成
不适用
Wearable Blood Pressure MonitoringBlood PressureNCT04218032University of Turku65
已完成
不适用
Use of NAVA-catheter Positioning Screen to Identify Different Cardiac ArrhythmiasCardiac ArrhythmiaNCT02040675ProMedica Health System5